Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 1, 2018, Pages

  Weiss, William J ^a   Pulse, Mark E ^a   Nguyen, Phung ^a   Peterson, Kelly ^a   Silva, Jessica ^a   Simecka, Jerry W ^a   Valtierra, David ^a   Sabet, Mojgan ^b   Griffith, David C ^b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b Medicines Company   (United States)

Author keywords

Klebsiella pneumoniae carbapenemase; KPC; Meropenem; Pyelonephritis; Vaborbactam

Indexed keywords

MEROPENEM; VABORBACTAM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BORONIC ACID DERIVATIVE; CARBAPENEMASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; COLONY FORMING UNIT; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTERIACEAE INFECTION; EVALUATION STUDY; FEMALE; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PYELONEPHRITIS; ANIMAL; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; ESCHERICHIA COLI; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BORONIC ACIDS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MEROPENEM; MICE; MICROBIAL SENSITIVITY TESTS; PYELONEPHRITIS; URINARY TRACT INFECTIONS;

EID: 85039804469     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01439-17     Document Type: Article

References (10)

1. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13:785-796. https://doi. org/10. 1016/S1473-3099(13)70190-7.
2. U. S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the UnitedStates, 2013. Centers for Disease Control and Prevention, Atlanta, GA. https://www. cdc. gov/drugresistance/threat-report-2013/index. html.
3. Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN. 2015. Discovery of a cyclic boronic acid -lactamase inhibitor (RPX7009) with utility versus class A serine carbapenemases. J Med Chem 58:3682-3692. https://doi. org/10. 1021/acs. jmedchem. 5b00127.
4. Castanheira M, Rhomberg PR, Flamm RK, Jones RN. 2016. Effect of the -lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 60:5454-5458. https://doi. org/10. 1128/AAC. 00711-16.
5. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, Landman D. 2015. Activity of meropenem combined with RPX7009, a novel -lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 59:4856-4860. https://doi. org/ 10. 1128/AAC. 00843-15.
6. Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Lomovskaya O, Dudley MN, Griffith DC. 2014. In vivo efficacy of Carbavance (meropenem/RPX7009) against KPC-producing Enterobacteriaceae, abstr F-959. Abstr 54th Intersci Conf Antimicrob Agents Chemother, American Society of Microbiology, 5 to 9 September 2014, Washington, DC.
7. Clinical and Laboratory Standards Institute (CLSI). 2015. Performance standards for antimicrobial susceptibility testing, 25th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Institute of Laboratory Animal Resources Commission on Life Sciences, National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
9. Griffith DC, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN. 2017. Pharmacodynamics of vaborbactam when administered in combination with meropenem, abstr Sunday 194, ASM Microbe 2017. American Society of Microbiology, 1 to 5 June 2017, New Orleans, LA.
10. Monogue ML, Nicolau DP. 2017. Translational efficacy of humanized exposures of cefepime, ertapenem, and levofloxacin against extendedspectrum-lactamase-producing Escherichia coli in a murine model of complicated urinary tract infection. Antimicrob Agents Chemother 61: e01329-17. https://doi. org/10. 1128/AAC. 01329-17.